Cartilage Biomarkers in Ankylosing Spondylitis Relationship to Clinical Variables and Treatment Response

被引:47
作者
Kim, Tae-Hwan [2 ]
Stone, Millicent [3 ]
Payne, Ursula [4 ]
Zhang, Xiang [4 ]
Ionescu, Mirela [5 ,6 ]
Lobanok, Tatiana [5 ,6 ]
King, Lindsay [7 ]
Poole, A. Robin [5 ,6 ]
Inman, Robert D. [1 ,4 ]
机构
[1] Toronto Western Hosp, Arthrit Ctr Excellence, Toronto Western Res Inst, Toronto, ON M5T 2S8, Canada
[2] Hanyang Univ, Hosp Rheumat Dis, Seoul 133791, South Korea
[3] St Michaels Hosp, Toronto, ON M5B 1W8, Canada
[4] Univ Toronto, Toronto, ON, Canada
[5] Shriners Hosp Children, Montreal, PQ, Canada
[6] McGill Univ, Montreal, PQ, Canada
[7] Ibex Technol, Montreal, PQ, Canada
来源
ARTHRITIS AND RHEUMATISM | 2005年 / 52卷 / 03期
基金
加拿大健康研究院;
关键词
D O I
10.1002/art.20870
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective. Ankylosing spondylitis (AS) is a progressive disease in which chronic inflammation can lead to extensive new bone formation throughout the spine. At present, few measures of the activity or extent of the disease are available. In this study, we sought to determine whether markers of cartilage synthesis and degradation could provide such quantitative measures. Methods. Serum samples from 23 patients receiving infliximab treatment for AS were obtained at baseline and at weeks 2, 6, 14, and 22. Patients were stratified with respect to joint involvement and baseline levels of inflammatory markers, and responders were defined according to the Assessments in Ankylosing Spondylitis 20% criteria. Serial measurements of interferon-gamma. tumor necrosis factor a, transforming growth factor beta (TGF beta), interleukin-10 (IL-10), and IL-1 were done at each time point. The following biomarkers were measured by enzyme-linked immunosorbent assay: the proteoglycan aggrecan 846 epitope, a marker of cartilage turnover; C-propeptide of type It collagen (CPII), a biosynthesis marker; and the Col2-3/4(long) (mono) (C2C) and Co12-3/4(short) (C1-2C) neoepitopes, reflecting collagen cleavage of type 11 collagen and type I/type 11 collagen, respectively. Results. At baseline, patients with AS demonstrated significant elevations in serum levels of CPII, the 846 epitope, and the CPII-to-C2C (CPII:C2C) ratio (but not C2C or C1-2C) compared with normal controls. Of the biomarkers examined, only CPII:C2C showed a correlation with the C-reactive protein (CRP) level. Among the biomarker-cytokine relationships, TGF beta demonstrated a trend toward a positive correlation with the 846 epitope. Conclusion. In AS, elevated serum levels of CPII and the 846 epitope may be related to biosynthetic turnover of hyaline cartilage and the intervertebral discs but may also reflect progressive bone formation as a result of endochondral ossification. The correlation of the CPII:C2C ratio with CRP suggests that the CPII: C2C ratio might prove to be a useful marker of disease activity in AS.
引用
收藏
页码:885 / 891
页数:7
相关论文
共 29 条
[1]  
BARALIAKOS X, 2004, ANN RHEUM DIS
[2]   Enhanced cleavage of type II collagen by collagenases in osteoarthritic articular cartilage [J].
Billinghurst, RC ;
Dahlberg, L ;
Ionescu, M ;
Reiner, A ;
Bourne, R ;
Rorabeck, C ;
Mitchell, P ;
Hambor, J ;
Diekmann, O ;
Tschesche, H ;
Chen, J ;
VanWart, H ;
Poole, AR .
JOURNAL OF CLINICAL INVESTIGATION, 1997, 99 (07) :1534-1545
[3]   EARLY SACROILIITIS IN PATIENTS WITH SPONDYLOARTHROPATHY - EVALUATION WITH DYNAMIC GADOLINIUM-ENHANCED MR-IMAGING [J].
BOLLOW, M ;
BRAUN, J ;
HAMM, B ;
EGGENS, U ;
SCHILLING, A ;
KONIG, H ;
WOLF, KJ .
RADIOLOGY, 1995, 194 (02) :529-536
[4]   Treatment of active ankylosing spondylitis with infliximab:: a randomised controlled multicentre trial [J].
Braun, J ;
Brandt, J ;
Listing, J ;
Zink, A ;
Alten, R ;
Golder, W ;
Gromica-Ihle, E ;
Kellner, H ;
Krause, A ;
Schneider, M ;
Sörensen, H ;
Zeidler, H ;
Thriene, W ;
Sieper, J .
LANCET, 2002, 359 (9313) :1187-1193
[5]   USE OF IMMUNOHISTOLOGIC AND IN-SITU HYBRIDIZATION TECHNIQUES IN THE EXAMINATION OF SACROILIAC JOINT BIOPSY SPECIMENS FROM PATIENTS WITH ANKYLOSING-SPONDYLITIS [J].
BRAUN, J ;
BOLLOW, M ;
NEURE, L ;
SEIPELT, E ;
SEYREKBASAN, F ;
HERBST, H ;
EGGENS, U ;
DISTLER, A ;
SIEPER, J .
ARTHRITIS AND RHEUMATISM, 1995, 38 (04) :499-505
[6]  
CALIN A, 1994, J RHEUMATOL, V21, P2281
[7]  
DOUGADOS M, 1988, J RHEUMATOL, V15, P302
[8]   Turnover of type II collagen and aggrecan in cartilage matrix at the onset of inflammatory arthritis in humans - Relationship to mediators of systemic and local inflammation [J].
Fraser, A ;
Fearon, U ;
Billinghurst, RC ;
Ionescu, M ;
Reece, R ;
Barwick, T ;
Emery, P ;
Poole, AR ;
Veale, DJ .
ARTHRITIS AND RHEUMATISM, 2003, 48 (11) :3085-3095
[9]   MEASUREMENT OF PATIENT OUTCOME IN ARTHRITIS [J].
FRIES, JF ;
SPITZ, P ;
KRAINES, RG ;
HOLMAN, HR .
ARTHRITIS AND RHEUMATISM, 1980, 23 (02) :137-145
[10]  
GARRETT S, 1994, J RHEUMATOL, V21, P2286